
News|Articles|March 1, 2011
FDA Pipeline Preview, March 2011 (Contrave, rabeprazole sodium extended-release capsules, Avodart, Mu Delta, Carfilzomib, Vascugel, INX-0818, vosaroxin, Acurox, fidaxomicin, melanoma cancer vaccine, NSI-566RSC, Regorafenib)
Recent FDA action (through, February 2011) related to Contrave, rabeprazole sodium extended-release capsules, Avodart, Mu Delta, Carfilzomib, Vascugel, INX-0818, vosaroxin, Acurox, fidaxomicin, melanoma cancer vaccine, NSI-566RSC, Regorafenib.
Advertisement
Complete response
Fast-track designation
Priority review
Orphan drug designations
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Older drug could slash blood transfusions during surgeries | ASH 2025
2
Catheter ablation shows benefits for patients with both aFib and sleep apnea
3
2025 FDA dermatology approvals: A new gene therapy and two targeted therapies
4
Sanofi’s Qfitlia seems favorable for hemophilia with easier dosing and broad coverage | ASH 2025
5





















































